Tallimustine in advanced previously untreated colorectal cancer, a phase II study.

Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previou...

Descripción completa

Detalles Bibliográficos
Autores principales: Punt, C. J., Humblet, Y., Roca, E., Dirix, L. Y., Wainstein, R., Polli, A., Corradino, I.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074363/
https://www.ncbi.nlm.nih.gov/pubmed/8611384
_version_ 1782137950822203392
author Punt, C. J.
Humblet, Y.
Roca, E.
Dirix, L. Y.
Wainstein, R.
Polli, A.
Corradino, I.
author_facet Punt, C. J.
Humblet, Y.
Roca, E.
Dirix, L. Y.
Wainstein, R.
Polli, A.
Corradino, I.
author_sort Punt, C. J.
collection PubMed
description Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previously untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 microgram m-2 once every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. Toxicity mainly consisted a highly selective neutropenia, which warrants further investigation of this agent in combination with myeloid growth factors.
format Text
id pubmed-2074363
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20743632009-09-10 Tallimustine in advanced previously untreated colorectal cancer, a phase II study. Punt, C. J. Humblet, Y. Roca, E. Dirix, L. Y. Wainstein, R. Polli, A. Corradino, I. Br J Cancer Research Article Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previously untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 microgram m-2 once every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. Toxicity mainly consisted a highly selective neutropenia, which warrants further investigation of this agent in combination with myeloid growth factors. Nature Publishing Group 1996-03 /pmc/articles/PMC2074363/ /pubmed/8611384 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Punt, C. J.
Humblet, Y.
Roca, E.
Dirix, L. Y.
Wainstein, R.
Polli, A.
Corradino, I.
Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
title Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
title_full Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
title_fullStr Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
title_full_unstemmed Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
title_short Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
title_sort tallimustine in advanced previously untreated colorectal cancer, a phase ii study.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074363/
https://www.ncbi.nlm.nih.gov/pubmed/8611384
work_keys_str_mv AT puntcj tallimustineinadvancedpreviouslyuntreatedcolorectalcanceraphaseiistudy
AT humblety tallimustineinadvancedpreviouslyuntreatedcolorectalcanceraphaseiistudy
AT rocae tallimustineinadvancedpreviouslyuntreatedcolorectalcanceraphaseiistudy
AT dirixly tallimustineinadvancedpreviouslyuntreatedcolorectalcanceraphaseiistudy
AT wainsteinr tallimustineinadvancedpreviouslyuntreatedcolorectalcanceraphaseiistudy
AT pollia tallimustineinadvancedpreviouslyuntreatedcolorectalcanceraphaseiistudy
AT corradinoi tallimustineinadvancedpreviouslyuntreatedcolorectalcanceraphaseiistudy

Ejemplares similares